

Special Issue

Recent Advances in Prevention and Treatment of Infectious Diseases

Message from the Guest Editors

Diseases caused by eukaryotic microorganisms have a high prevalence and a worldwide distribution, causing millions of deaths every year. However, the antimicrobial agents of choice against some of these infections are limited (e.g., malaria, candidiasis, leishmaniasis, toxoplasmosis, biofilm-related infections, amebiasis, keratitis, etc.). In addition, the majority of therapeutic treatments are associated with microorganism resistance, severe side effects due to toxicity, or limited activity against the causative agent of the disease. This Special Issue aims to assemble original research and review articles related to strategies to address the problems associated with these widely distributed infections; new advances in the development of effective strategies to control and treat eukaryotic infections, including new therapeutic treatments, new targets and new diagnosis systems; mechanisms of action; new delivery systems or combined therapy to enhance election treatment efficacy; new formulations to improve tolerability, among others.

Guest Editors

Prof. Dr. José Luis Copa Patiño

Dr. Irene Heredero-Bermejo

Dr. Natalia Gómez Casanova

Deadline for manuscript submissions

closed (31 December 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/79903

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).